Vyome Holdings, Inc.

Vyome to Present Compelling Phase 2 Clinical Data on VT-1953 for Treatment of MFW at AACR 2026

Vyome Reports Transformational 2025 Results: Company Well Positioned for Breakout Phase

Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity

Vyome Files for VT-1953 Orphan Drug Status, Furthers Strategic Focus On VT-1953 Program Over the Next 6 Months

Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results